Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated
thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology …

Objective The effectiveness of adjuvant radioiodine (RAI) after reoperation in patients with
persistent or recurrent differentiated thyroid cancer (DTC) is controversial. Although various …

Simple Summary Tumor recurrence is a relatively common event in papillary thyroid cancer
(PTC). The aim of this study was to analyze the time-varying pattern of recurrence in PTC …

Importance One-third of patients with papillary thyroid cancer (PTC) develop persistent or
recurrent disease after initial therapy. Most patients with persistent or recurrent disease …

Objectives Radioactive iodine (RAI) treatment is often indicated after total thyroidectomy in
differentiated thyroid cancer (DTC). However, its role in biochemical or locoregional …

Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …

Background Postoperative routine radioiodine (RAI) treatment is currently debated for
patients with low-risk differentiated thyroid carcinoma (DTC) patients. If performed, a low …

Background Most patients with papillary thyroid cancer (PTC) and lymph node metastases
(LNM) undergoing reoperation do not show apparent disease after this procedure, but …

Background Although lobectomy is considered acceptable as a primary surgical treatment
for papillary thyroid carcinoma in properly selected patients, a standard treatment for …

Introduction Patients with incomplete response to initial therapy of thyroid cancer can be
managed with ongoing observation or potentially additional therapies. Our aim was to …